Navigation Links
OMT announces a breakthrough in the development of a novel human antibody platform
Date:7/23/2009

Palo Alto, CA: July 23, 2009 Open Monoclonal Technology, Inc. (OMT), in collaboration with Sangamo BioSciences, Inc. (NASDAQ, SGMO), Sigma-Aldrich Corporation (NASDAQ: SIAL), The Medical College of Wisconsin, and INSERM, today announced the creation of the first targeted knockout rats as detailed in "Knockout Rats Produced via Embryo Microinjection of Designed Zinc Finger Nucleases," published in the July 24th issue of Science. The creation of rats with permanent, heritable genetic mutations is a critical milestone in the development of OMT's novel human monoclonal antibody platform.

"Creating a knockout rat was the biggest challenge OMT faced", said Dr. Roland Buelow, CEO of OMT and senior author of the paper. "Inactivation of endogenous rat antibody expression is essential for human antibody expression in genetically engineered animals. To solve this problem, we explored a new application for Zinc Finger Nuclease (ZFN) technology, which enabled a technique that could revolutionize the genetic engineering of animals."

In the study, OMT scientists and its collaborators used ZFNs developed by Sangamo BioSciences, Inc. to knockout a gene encoding rat immunoglobulin. The mutations in rat immunoglobulin caused no off-target effects in other genes, and offspring of the ZFN-edited rats carried the mutated genes. Together, these results demonstrate the ability to generate heritable, specific and permanent modifications in a mammal using standard microinjection techniques and engineered ZFNs in early-stage embryos.

With antibody sales expected to reach $50 billion within five years, many companies have entered the biologics market through acquiring antibody technologies or licensing/fee for service arrangements. Currently, the mouse is the only genetically engineered animal commercially available for the generation of human monoclonal antibodies, and many targets are licensed already. The expense and limitations of the mouse technology create an opportunity for OMT and its new monoclonal antibody platform with unrestricted development options.

OMT's human antibody technology is the result of an improved understanding of B-cell development and a novel approach to the inactivation of endogenous antibody expression described in the "Science" article. Previously, it took either embryonic stem cells or nuclear transfer cloning -- techniques that are not available for the genetic engineering of rats to create a knockout, OMT used a new ZFN-mediated technique to generate immunoglobulin knockout rats. ZFNs are engineered proteins that induce double-strand breaks at specific sites in an organism's DNA. Such double-strand breaks stimulate the cell's natural DNA-repair pathways and can result in site- specific changes in the DNA sequence. Up to now, ZFNs have been used to edit specific genes in fruit flies, worms (C. elegans), cultured cells and zebrafish embryos, but this is the first example of successful, permanent, heritable gene-editing in a mammal.


'/>"/>

Contact: Dr. Roland Buelow
rbuelow@omtinc.net
650-224-6835
Open Monoclonal Technology, Inc.
Source:Eurekalert

Related biology technology :

1. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
2. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
4. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
5. Response Genetics Announces $4 Million Private Placement
6. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
7. Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech, Inc. Sales in Emerging Markets
8. NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region
9. Thomson Reuters Announces 2009 Edition of the CMR International Pharmaceutical R&D Factbook
10. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
11. Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Clinovo , the ... validated Electronic Data Capture (EDC) system ClinCaptureand its new Contract Research Organization (CRO) ... 2016 Conference in San Mateo, California on February 10th and 11th. Watch ...
(Date:2/9/2016)... ... February 09, 2016 , ... The American Academy of ... it is offering its 2016 AAT Member Certification Qualification Course for Technicians via a ... the webinar, which will include a detailed review of hardware, software, and camera setup/operations, ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... for Public Policy for the National Organization for Rare Disorders (NORD). Dorman will ... ensure their voices are heard throughout the drug regulatory review process. , “Adding ...
(Date:2/9/2016)... 2016 This market research report on the ... prospects of the market in terms of revenue (USD ... in the manufacture of microbiology culture media and related ... market snapshot providing the overall information of various market ... section also provides the overall information and data analysis ...
Breaking Biology Technology:
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... Technology Enhancements Accelerate Growth of X-ray Imaging ... and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth analysis ... as regional market drivers and restraints. The study offers ... market attractiveness, both for digital and computed radiography. Market ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
Breaking Biology News(10 mins):